In Europe, an estimated 6.5M people are affected by heart valve disease (HVD) each year. Tricuspid regurgitation (TR) is a HVD which occurs when the tricuspid valve fails to close properly, causing blood to flow backward into the right atrium. Many cases of TR are accompanied by Right Ventricle (RV) Dysfunction. The gold standard methods for tricuspid valve diseases are standard open-heart surgery and transcatheter valve replacement. However, high-risk interventions require long recovery time long in-hospital stays and have significant hospital mortality (more than 10%). Due to the high risk related to the surgical procedure, most of the patients cannot be treated. As such, there is a significant unmet clinical need for a transcatheter solution to TR.
Trisol is introducing the Trisol System, a transcatheter tricuspid valve replacement system for treating severe TR and preventing RV dysfunction. The Trisol valve uses a flexible delivery system to position the valve into the heart with support arms anchoring to the tricuspid physiological site. The Trisol System allows cardiologists to perform a quick and safe implant procedure (30 minutes compared to 2-4 hours of standard surgery) thus increasing the number of treated population and reducing in hospital and recovery time. Moreover, it will increase heart performance and reduce the risk of mortality typical of open-heart surgeries.